Our Founders
-
Professor Stephen Jackson
Founder & Chief Scientific Officer
Stephen Jackson is a Founder and Chief Scientific Officer of Neurotherapeutics Ltd, Professor of Cognitive Neuroscience at the University of Nottingham and has over 30 years research experience investigating human sensorimotor function in health and disorder.
He is the first recipient of the ‘Dirk Bakker Visiting Professorship’ awarded by the Stichting Neuropsychologie Nederland (Dutch Neuropsychology Society) and is currently Chair of the Scientific Advisory Board of the Federation of European Societies for Neuropsychology (FESN). Stephen has previously served as President of the British Association for Cognitive Neuroscience (BACN), Director of the University of Nottingham’s Institute of Neuroscience and from 2007–2012 he chaired a European Research Network Programme (RNP) on ‘Human Sensorimotor Function in Health and Disease’.
His research has been funded by many funding organisations including: the Wellcome Trust; NIHR; MRC; BBSRC; BUPA Foundation; Tourette Association of America; and Tourettes Action and he has provided scientific advice and guidance to a wide range of governmental, industrial, academic and charitable organisations including the UK Ministry of Defence, Unilever, the MRC and Wellcome Trust. From 2009 – 2012 Stephen was appointed ‘Distinguished Overseas Professor’ at Korea University, South Korea. His role was to assist in establishing a new centre for research and teaching excellence in ‘Brain and Cognitive Engineering’ at Korea University and to lead a research team investigating Brain Plasticity Mechanisms. -
Emeritus Professor Georgina Jackson
Founder, Non-executive Director & Senior Science Officer
Georgina Jackson is a Founder, Director and Senior Science Officer of Neurotherapeutics Ltd and Emeritus Professor of Cognitive Neuropsychology, School of Medicine, University of Nottingham.
She has an extensive track-record of externally funded research investigating the brain mechanisms underlying goal-directed behaviour in health and disorder. Her work has focused on understanding the development of cognitive control processes (often referred to as executive function) during childhood and adolescence and how these processes are affected by neurodevelopmental conditions such as Tourette Syndrome (TS). Over the past ten years she has focused on non-pharmacological treatments for TS publishing on the therapeutic impacts of exercise and more recently the use of median nerve stimulation.
She has been funded by the Wellcome Trust, MRC, BBSRC, ESRC, NIHR amongst others and has been actively involved in Tourette Syndrome research for over twenty years. In 2009 she was commissioned by UK charity Tourettes Action, with funding from the Big-Lottery Fund, to examine the psycho-social experiences of young people with Tourette Syndrome and she co-authored a Healthcare Technology Association report on the clinical effectiveness and patients perspectives on treatments for TS. Georgina has previously served as General Secretary of the British Neuropsychological Society and a member of the Board of Trustees of Tourettes Action (2014-2023). -
Dr. Barbara Morera
Chief Research Officer
Barbara carried out the research studies leading to the technology that Neurotherapeutics Ltd is developing into a wearable medical device aimed at controlling symptoms of Tourette Syndrome.
With over seven years of focused research on Tourette Syndrome, Barbara has worked closely with those affected by the condition. She oversees all research activities with the goal of enhancing the quality of life for individuals with Tourette Syndrome.
Our board of directors
-
Ian Rhodes
Chair of the board
Ian is currently serving as Chair of the Board and Non-Executive Director for Neurotherapeutics Ltd.
Ian was involved as an Investor Director during the early company formation, an engineer by background bringing over 35 years’ experience of working with new technologies and the Life Sciences. Previously, Ian was the CEO of McLaren Applied Technologies and former Senior Partner at PA Consulting Group where he delivered value to many of the global corporations and investors across the Life Sciences. -
Emeritus Professor Georgina Jackson
Founder, Non-executive Director & Senior Science Officer
Georgina has over 35 years of research experience and 20 years investigating Tourette Syndrome.
Her current work focuses on support the development of safe and effective therapies for home use in brain health conditions which are informed by patient experience. -
Dr. Barbara Morera
Chief Research Officer / Director
With over 7 years of focused research on Tourette Syndrome, Barbara has worked closely with those affected by the condition. She oversees all research activities with the goal of enhancing the quality of life for individuals with Tourette Syndrome. -
James Duncan
Investor / Observer
James is a member of the team at Nottingham Technology Ventures Ltd, the subsidiary company of the University of Nottingham responsible for the formation of and investment in spin out companies.
A life scientist by training he has over 20 years of experience working both in industry and university technology transfer including holding a number of board positions. -
Paul Cable
Chief Executive Officer / Director
Paul has over 30 years of experience in the medical device and pharmaceutical field, working previously for Baxter Healthcare and lately through his own consultancy working with startups and established businesses.
Paul helped the University of Nottingham to spin out Neurotherapeutics Ltd and has lead the company as CEO since February 2021. -
Andrew McNeill
Investor / Director
Andrew holds a PhD in Molecular Physics and has over 15 years’ experience in leading early stage venture capital backed medical device and biotech companies. Andrew joined the board in early 2024. -
Karl Moss
Independent Non-executive Director
Karl has spent over 20 years actively running or consulting on a range of ecommerce businesses, including online retailers, ticketing and travel providers and most recently DTC (Direct to Consumer) brands.
He can be plugged into the detail of operations, marketing and logistics, while also providing strategic leadership on growth and industry developments. He also has wealth of experience dealing with global marketplaces and how businesses can operate alongside and within them. -
David O'Reilly
Independent Non-executive Director
David has over 25 years of experience in founding, financing and commercialising innovative pharmaceutical, medical device and digital health companies.
He is Managing Director of Bayview Biosciences and serves on the boards of several medical technology and nonprofit organizations. David joined the Neupulse Board of Directors in 2024 and is supporting our US strategy and commercialisation. -
Sandy Reid
Board Observer
Sandy had over 15 years senior management and director experience. -
Amanda Larkin
Observer / Finance Director
Amanda has over 20 years’ experience working in Finance.
Our Senior Management Team
-
Paul Cable
Chief Executive Officer / Director
Paul has over 30 years of experience in the medical device and pharmaceutical field, working previously for Baxter Healthcare and lately through his own consultancy working with startups and established businesses.
Paul helped the University of Nottingham to spin out Neurotherapeutics Ltd and has lead the company as CEO since February 2021. -
Dr. Barbara Morera
Chief Research Officer
Barbara carried out the research studies leading to the technology that Neurotherapeutics Ltd is developing into a wearable medical device aimed at controlling symptoms of Tourette Syndrome.
With over seven years of focused research on Tourette Syndrome, Barbara has worked closely with those affected by the condition. She oversees all research activities with the goal of enhancing the quality of life for individuals with Tourette Syndrome. -
Dr. David Moser
Chief technology Officer
Dr David Moser is an experienced engineer in the areas of Robotics and Medical devices. He brings over 17 years of experience developing wearable assistive technologies and medical devices.
He is former Director of Research and Technology at Blatchford where he led the development of some of the world’s most advanced prosthetics and a succession of award-winning products including the RAEng MacRobert Award finalist in 2010, winner in 2016 and the US Medical Device excellence award in 2017.
He is a Chartered Engineer and a Visiting Professor at the University of Southampton. He holds over 25 patents and has published extensively in the areas of prosthetics, body interface technologies, Robotics, physical rehabilitation and digital health. He is responsible for technology and new product development. -
Claire Hall
Quality & Regulatory Manager
Claire has over 20 years of experience in quality management practices, ISO certification and regulatory affairs predominantly within the medical device and pharmaceutical industries.
She is responsible for our Quality Management System, ISO certification, Data Protection and Health, Safety and Wellbeing. -
Ben Garland
eCommerce Operations Officer
Ben joins us with over 18 years’ experience in ecommerce, project management and marketing. Ben is responsible for our digital sales and marketing activities.
